Melanoma TrialFinder

For patients

Find a trial

21 trials in 46 locations

MONETTE: A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

This trial aims to investigate how effective ceralasertib alone or the combination treatment of ceralasertib and durvalumab are at treating advanced melanoma in patients who have disease progression while receiving standard immunotherapy treatment.The trial also aims to look at how well patients cope with these treatments, for example, if they experience any side effects.Ceralasertib is a treatment that has been shown to be effective at treating different types of cancers in many clinical trials. [...]

Locations: Addenbrookes Hospital, The Royal Marsden Hospital (LONDON), Mount Vernom Hospital, The Royal Marsden Hospital (SURREY)

NAVIGATE: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children with NTRK-fusion Positive Solid Tumours

The trial aims to investigate if larotrectinib is effective at treating solid tumours with an NTRK positive gene mutstion.The trial also aims to look at how well patients tolerate treatment with larotrectinib, for example, if they might experience any side effects. Larotrectinib is a treatment that has just been licensed to treat solid tumours with an NTRK gene mutation, including NTRK positive melanoma. It is known as a TRK inhibitor. These types of treatments [...]

Locations: Beatson West of Scotland Cancer Centre, University College London Hospitals NHS Foundation Trust (UCLH),

THETIS (ATX-ME-001): ATL001 in Patients with Metastatic or Recurrent Melanoma

The trial aims to investigate how safe ATL001 is when it is used to treat melanoma and if patients experience any adverse events with the treatment.The trial also aims to measure how effective ATL001 is for treating melanoma, and how well it works when given with high or low-dose interleukin-2 (Il-2) or in combination with nivolumab immunotherapy ATL001 is made up of cells taken from your own melanoma, known as clonal neoantigen reactive T [...]

Locations: University College London Hospital (UCLH), Cambridge University Hospitals NHS Foundation Trust, University Hospital Southampton, The Royal Marsden Hospital (LONDON), Guys and St Thomas's NHS Foundation Trust, Freeman Hospital, The Christie NHS Foundation Trust

DETECTION: Circulating Tumour DNA Guided Therapy for Stage 2B or 2C Melanoma After Surgical Resection

In light of new adjuvant treatment approved by the NHS for patients with Stage 2 melanoma, the design of this trial is being updated. During this time recruitment of new patients to this trial is closed.After patients have had their melanoma completely removed (resected) by surgery, currently, they are not given any drug treatment afterwards and doctors monitor them at regular intervals to ensure that their melanoma has not returned. This trial aims to [...]

Locations: Churchill Hospital, Nottingham City Hospital, Addenbrookes Hospital, The Christie NHS Foundation Trust, The Beatson West of Scotland Cancer Centre

DANTE: Duration of Anti-PD1 therapy for melanoma

At the moment, clinicians aren’t sure how long to give PD-1 inhibitor treatment for to patients with advanced melanoma. The current practice is to treat for at least two years if the patient continues to benefit and can tolerate treatment. However, the treatment seems to make the most difference within the first year and there is evidence to suggest that the treatment could be as effective and cause fewer side effects if it [...]

Locations: This trial is no longer recruiting new patients

MISST: Melanoma Immunomodulation and Immune Responses of the Skin Study: A Translational Science Research Protocol

This study aims to better understand how genes as well as the immune system affect the development of melanoma. Researchers hope that the results could improve how melanoma is detected and also lead to the development of new treatments for melanoma.The early stages of melanoma can be treated effectively by using surgery to remove the melanoma, but no cure is available at the moment in more advanced melanoma. Doctors currently don’t know what causes [...]

Locations: Guy's and St Thomas' NHS Trust

MelMarT-II: Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

The trial aims to look at how long patients stay free from melanoma after different types of surgery to remove the disease. A wide local excision involves removing an extra "safety margin" of skin around the original melanoma site, to make sure that any remaining scattered melanoma tumour cells that may have been left behind after the first biopsy/surgery are removed. At the moment melanoma specialists don’t know the ideal width of excision [...]

Locations: The Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Trust, Nottingham University Hospitals NHS Trust, Royal Cornwall Hospital, Queen Victoria Hospital NHS Foundation Trust, Hull University Teaching Hospitals NHS Trust, Oxford University Hospitals NHS Foundation Trust, Norfolk and Norwich University Hospital, Guys and St Thomas' NHS Foundation Trust, North Bristol NHS Trust, The Leeds Teaching Hospitals NHS Trust, St George's University Hospitals NHS Foundation Trust, Royal Free London NHS Foundation Trust, University Hospitals Birmingham NHS Foundation Trust, Mid and South Essex NHS Trust, St Helen's & Knowsley Hospitals Trust, South Tees Hospitals NHS Foundation Trust of The James Cook University Hospital

MITRE: Microbiome Immunotherapy Toxicity and Response Evaluation

The MITRE study aims to investigate whether there is a gut microbiome ‘signature’ (pattern) which can predict which patients receiving immune checkpoint inhibitors are likely to respond to treatment.The study also aims find out whether there is a link between the gut microbiome and risk of severe side effects associated with immune checkpoint inhibitor treatment. Gut Microbiome: People have hundreds of thousands of different types of natural bacteria living in the gastrointestinal tract, which [...]

Locations: Weston Park Hospital, Velindre Cancer Centre, Bristol Haematology and Oncology Centre, Norfolk and Norwich University Hospitals, Somerset NHS Foundation Trust, Royal Cornwall Hospital, Western General Hospital, Addenbrookes, Cambridge University Hospitals NHS Trust, Royal United Hospital Bath, University Hospital Southampton, Leicester Royal Infirmary, Royal Bournemouth Hospital

MAAM Study: Microwave Ablation in Advanced Melanoma Study

This trial aims to investigate if Microwave ablation (MWA) can be used to destroy and remove cutaneous melanoma metastases and also if it can help to stimulate the body’s natural defence ( immune system ) to attack the melanoma cells.This trial also aims to look at how patients tolerate the MWA treatment, through questionnaires and asking the patient to write notes in a pain diary.Microwave ablation (MWA) is a process that creates heat from [...]

Locations: University Hospital Southampton

MoleGazer: MoleGazer Development Feasibility Study

Melanoma can often develop from moles that already exist on your skin. Currently dermatologists will aim to review and identify new and changing moles in patients who have lots of moles on their body by using total body photography.Total body photography (TBP) is a method of taking high-quality photographs of a patient’s entire skin, so that doctors can track, compare and monitor moles over time. This has been shown to improve melanoma diagnosis.TBP is [...]

Locations: Churchill Hospital

ARTISTRY-6: Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma

The trial aims to investigate how effective nemvaleukin alfa is at treating unresectable and/or metastatic melanoma in patients who have previously received immunotherapy treatment with a PD-1 inhibitor for their melanoma.The trial also aims to look at how well patients cope with the treatment, for example, if they experience any side effects.The researchers also want to see if there is any difference to how well the drug works if the nemvaleukin alfa is given [...]

Locations: Oxford University Hospitals NHS Foundation Trust, THE ROYAL MARSDEN HOSPITAL (LONDON), The Christie NHS Foundation Trust

PECan: PDL1 Expression in Cancer

In this study, researchers want to find out if using 99mTc-labelled PD-L1 SPECT (see below for explanation) in melanoma patients, can help to predict how effective PD-1 inhibitor immunotherapy treatment will be to treat their melanoma. Usual standard scans will be carried out as well, so that the researchers can compare the two against each other.Currently, to see how well treatment is working for a melanoma patient doctors will use standard external (non-invasive) scans, [...]

Locations: Guy's and St Thomas' NHS Trust

The SCOPE Study: SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab

The trial aims to investigate if SCIB1 can be used safely as a combination treatment with current standard immunotherapy treatments, either nivolumab with ipilimumab or pembrolizumab.The trial also wants to look at how effective the combination treatment is at treating melanoma.Pembrolizumab is a standard immunotherapy treatment that is already used to treat different stages of melanoma. It stimulates the body’s natural defence ( immune system ) to attack and kill cancer cells.Nivolumab is a [...]

Locations: Royal Preston Hospital, Somerset NHS Foundation Trust, Churchill Hospital, Oxford University NHS Trust, Mount Vernon Hospital, East and North Hertfordshire NHS Trust, Nottingham University Hospitals NHS Trust, Weston Park Hospital, Velindre University NHS Trust

IGNYTE: Study of RP1 Monotherapy and RP1 in Combination with Nivolumab

In the phase 1 part of the trial, the aim was to investigate the safest dose of the experimental treatment; RP1, that patients can receive. Researchers then explored the safest dose of RP1 in combination with nivolumab, a PD1-inhibitor.Once the researchers have decided the safest doses, the phase 2 of the trial will look at how effective RP1, as a combination treatment with nivolumab, is at treating all types of melanomas, as well as [...]

Locations: The Clatterbridge Cancer Centre NHS Foundation Trust, The Royal Marsden Hospital (LONDON), St James's University Hospital, University Hospital Southampton, Churchill Hospital, Beatson West of Scotland Cancer Center

TebeMRD: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

This trial aims to look at how to treat patients with resected cutaneous melanoma who are thought to have a medium or high risk of the melanoma coming back, or patients with a diagnosis of uveal melanoma.This research will use a new blood test to see if there are any tiny amounts of melanoma cells in the body, which wouldn’t normally be seen on standard CT scans. This blood test can help doctors decide [...]

Locations: Churchill Hospital, Mount Vernon Cancer Centre

TEBENTAFUSP: Tebentafusp Managed Access Program for Metastatic Uveal Melanoma

Uveal melanoma is generally treated with either chemotherapy or drugs that work by activating the body’s natural defence ( immune system ), known as immunotherapy. Some melanomas can avoid being seen or detected by the patient's own immune system, so that they can’t be attacked or killed. immunotherapy works by stimulating the immune system to work against the melanoma by turning on or turning off certain signals in the immune system, to allow the [...]

Locations: Norfolk and Norwich University Hospital, The Royal Marsden (LONDON), Belfast City Hospital, Bristol Haematology and Oncology Centre, Royal Preston Hospital, Poole Hospital, Cheltenham General Hospital, William Harvey Hospital, Castle Hill Hospital, East and North Hertfordshire NHS Trust, Nottingham City Hospital, University Hospital Birmingham, Musgrove Park Hospital, The Beatson West of Scotland Cancer Centre, The Christie NHS Foundation Trust, Royal Cornwall Hospital, The Clatterbridge Cancer Centre - LIVERPOOL, The Freeman Hospital

IMP-MEL: Testing IMM60 in combination with pembrolizumab in melanoma and non-small cell lung cancer

The phase 1 of this trial aims to look at how safe the experimental treatment IMM60 is when it is given to patients. Researchers will look at how well patients cope with the treatment at different doses and if they experience any side effects. Once the safe dose of IMM60 is known it will be given to patients as a combination treatment with pembrolizumab, an immunotherapy drug that is already used in the treatment [...]

Locations: John Radcliffe Hospital, Hammersmith Hospital

OOB: The Liverpool Ocular Oncology Biobank

The Liverpool Ocular Oncology Biobank (OOB) works closely with local and regional hospitals in the UK to collect and store ocular biosamples, blood and associated clinical data from consenting patients for use in research relating to eye cancers and other eye diseases. Biosamples are small parts of tissue that are removed from the ocular tumour so that doctors or researchers can analyse them.The biobank aims to build a valuable collection that will be used [...]

Locations: The Liverpool Ocular Oncology Centre

BNT111-01: Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage 3 or 4 Melanoma

This trial aims to investigate how effective the combination therapy of BNT111 and cemiplimab is at treating patients with stage 3 or stage 4 cutaneous melanoma who have previously had PD-1 inhibitor immunotherapy treatment, but it hasn’t worked.The trial will also look at how well patients cope with the combination treatment, for example, if they experience any side effects.BNT111 is an experimental therapeutic cancer vaccine. Therapeutic cancer vaccines aim to stimulate the body’s natural [...]

Locations: Royal Cornwall Hospital, The Christie NHS Foundation Trust

INITIUM STUDY: UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Currently the first line treatment for patients that have unresectable melanoma is with immunotherapy. This trial aims to investigate if the use of UV1 vaccination in combination with ipilimumab and nivolumab immunotherapy is more effective at treating unresectable stage 3B,3C, 3D or 4 cutaneous melanomas than treating with immunotherapy alone, which is the current standard therapy.The trial also wants to look at how well patients tolerate the UV1 vaccination in combination with ipilimumab and [...]

Locations: The Christie NHS Foundation Trust

OPTIC: Views on Optimising Immune Checkpoint Inhibition in Cancer

This research study aims to look at patient views on changing the way immunotherapy treatments are given for different types of cancer, including melanoma.immunotherapy treatment works by encouraging the body’s own immune system to fight against melanoma cells. immunotherapy treatment can be given to patients: - whose melanoma has been treated with surgery and has not spread to other parts of the body. In this case it aims to prevent or delay cancer from coming [...]

Locations: This will take place online; anyone in the UK can take part